StemCell Therapy

Click here to read the full article.

Coming in as the seventh-most deadly disease in the United States, diabetes isnt something you want to ignore. But according to research conducted by the American Diabetes Association, 32.3 million Americans had diabetes in 2015 but a whopping 7.2 million of them went diagnosed. What gives?

There are common signs to diabetes, such as frequent urination, increased thirst, weight loss, blurred vision and fatigue, Lucille Hughes, a registered nurse and director of diabetes education for South Nassau Communities Hospital and treasurer of the American Association of Diabetes Educators, tells SheKnows. However, many signs and symptoms of diabetes are vague and can be a symptom of other things.

More from SheKnows

This is especially true for women. While rates of diabetes are relatively equalacross the board, there are several signs of diabetes that are unique to women that you may not have even realized. Especially as November is National Diabetes Month, here are some of the red flags you may be overlooking.

Believe it or not, some urogenital conditions can be signs of diabetes.

Genital symptoms may show up more in women than in men, Dr. Margo Hudson,a Harvard Medical School instructor and physician at the Fish Center for Womens Health at the Brigham and Womens Hospital in Boston, told SheKnows. A typical case is a woman with recurrent yeast infections and recurrent urinary tract infections who goes to the gynecologist and also finds high blood sugar.

Hughes explains that diabetes causes more glucose to be excreted in your urine, leading to these increased tract infections. However, she also points out that some of these symptoms are often misunderstood, especially by older, postmenopausal women.

Menopause brings about changes in a womans body, such as increased weight, vaginal dryness and discomfort during sexual intercourse, Hughes says. Vaginal dryness and discomfort during sexual intercourse are also signs of diabetes, and weight gain puts a woman at risk for diabetes.

As this risk increases as both men and women age, it is important to note these overlapping symptoms.

In addition to vaginal yeast infections, oral yeast infections (AKA cases of oral thrush) are also a common sign to look out for. You may see white patches, experience redness or soreness in your mouth, have swollen red gums or the inner parts of your cheek or experience trouble eating or swallowing because of these infections.

Polycystic ovarian syndrome is a hormonal disorder that occurs when a person with ovaries produces an excess of androgens. If it is not treated, it can lead to a number of complications, including diabetes.

The common denominator of PCOS and diabetes is insulin resistance, a condition that up to 70 percent of people with PCOS exhibit. But while insulin resistance is understood to be a cause of diabetes, medical professionals are not sure whether this condition is a consequence or a cause of PCOS.

With diabetes, we can measure blood sugar and you meet criteria or you dont, Hudson explains. With PCOS, there is no single marker. In my practice, patients are often first diagnosed with diabetes, and it is not until you put together their whole medical history that you realize that the patient also has PCOS.

And since its estimated that almost half of PCOS cases go undiagnosed, it may not be the most recognizable sign of diabetes. But if you have already been diagnosed with PCOS, talk to your health care provider about managing your insulin, and thus mitigating your risk for developing diabetes.

Gestational diabetes is a specific type of diabetes that only appears when people are pregnant, causing high blood sugar levels that could harm both the pregnant person and the baby.

Most women are not aware they have gestational diabetes, Hughes says. Keep in mind that some of the symptoms of diabetes, such as increased thirst, increased urination and fatigue are all common in pregnancy, so they may not trigger an expecting mom to seek medical attention.

According to Hughes, women are especially at risk if they have developed gestational diabetes in a previous pregnancy, if they have previously given birth to a child weighing more than 9 pounds or if their body mass index is over 30. She suggests that all women get screened for gestational diabetes within the first 24 to 28 weeks of their pregnancy to best manage the potential health risks.

Typically, with proper medical attention, these cases of diabetes disappear after the baby is born. Problem solved, right?

Not so fast.

Gestational diabetes is a huge warning sign to patients, Hudson explains. Depending on their ethnicity, these patients have anywhere from a 50 to 70 percent chance of getting diabetes later in life.

While this sounds a little scary to any new moms out there, Hudson points out that this indicator may actually be a good thing, as patients can now understand and manage their risk at an earlier age.

While the signs of diabetes seem to be scattered around different medical specializations, dont be afraid to talk to a medical professional about symptoms that seem to be unrelated.

Whether it is a gynecologist, a [physician assistant] or a nurse practitioner at a walk-in center, a patient needs to tell all of their symptoms, Hudson says. It will not take the system long to figure out what the problem is and who within the system would be the best person the patient needs.

So when in doubt, ask a medical practitioner about any symptoms you think might be a sign of diabetes. The sooner you are diagnosed, the sooner youll be able to start getting the treatment you need.

Sign up for SheKnows' Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

Read the rest here:
These Are the Signs of Diabetes in Women - Yahoo Lifestyle

Nitt Hanprathet,1 Somrat Lertmaharit,1 Vitool Lohsoonthorn,1,2 Thanapoom Rattananupong,1 Palanee Ammaranond,3 Wiroj Jiamjarasrangsi1,2

1Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; 2Department of Preventive and Social Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand; 3Department of Transfusion Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand

Correspondence: Wiroj JiamjarasrangsiDepartment of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Pathumwan, Bangkok 10330, ThailandTel +66 2 256 4000 ext. 3700Fax +662 256 4292Email wjiamja@gmail.com

Purpose: The gender differential evidence of the association between shift work and type 2 diabetes risk remains scarce. This longitudinal study determines whether the association between shift-work exposure and type 2 diabetes risk and abnormal fasting plasma glucose (FPG) differs according to gender; the study aims to find the association between shift work and changes in physiological, behavioral, and psychosocial stress.Patients and methods: This retrospective cohort study was conducted among 5947 workers (4647 female and 1300 male) aged 60 years old in Bangkok, Thailand. Participants required a normal FPG level (<100 mg/dL) at baseline and at least two health check-up results from 2009 to 2016. Shift-work exposure history was assessed using a self-administered questionnaire; FPG levels were measured annually. Cox proportional hazard models were used to assess the aforementioned association.Results: During the follow-up period, 1470 new abnormal FPG and 154 new type 2 diabetes cases developed. Stratified analysis of male workers data revealed an association was significant in the unadjusted model, which tended to be stronger after adjustment for demographic data and the baseline values of anthropometric and biochemical parameters. This was the case both for type 2 diabetes [Hazard Ratio (HR) (95% Confidence Interval (CI))=2.98 (1.585.62)] and abnormal FPG [HR (95% CI)=1.86 (1.432.41)]; this association was less obvious among women.Conclusion: Shift work is a risk factor for type 2 diabetes and abnormal FPG; this risk is gender differential, being more pronounced in men. Preventive measures aiming at ameliorating shift work induced type 2 diabetes risk should pay more attention to men.

Keywords: shift-work exposure, diabetes, abnormal fasting plasma glucose, gender difference, behavioral stress, retrospective cohort study, Cox proportional hazard models

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post:
Increased Risk Of Type 2 Diabetes And Abnormal FPG Due To Shift Work D | DMSO - Dove Medical Press

Community comes together to help find a cure for diabetes

IMPERIAL, Calif. - Dozens filled the track at Imperial Valley College on Saturday,for the inaugural "Juvenile Diabetes Research Foundation One Walk",to help raise awareness for those battling diabetes.

Matthew Jaime, one of the event organizers saidImperial County has one of the highest rate of incidences involving diabetes.

They hope the walk will have an impact onthe current health care for local diabetics.

"An event like this is a testament to the fact that we can make improvements in the way that we approach care to diabetes here in the Imperial Valley. And that just because we're our own little community out here in the desert doesn't mean that we can't bring the resources down to our people. And this event is a testament to that," said Jaime.

Funds raised at the walk go towards research to find a cure for type one diabetes. For a link to local agencies that help residents prevent diabetes you can click here.

The rest is here:
Community comes together to help find a cure for diabetes - KYMA

LAS VEGAS An investigational agent, bimagrumab (Novartis) which was originally being tested to see if it would increase lean muscle mass in people with sarcopenia is effective and safe for weight loss, according to preliminary results from a study in patients with obesity and type 2 diabetes.

Laura A. Coleman, PhD, RD, a researcher at Novartis in Cambridge, Massachusetts, presented intriguing phase 2 trial findings with this activin receptor antagonist here in a late-breaking research forum before the start of Obesity Week 2019.

The investigators randomly assigned 75 patients with obesity and type 2 diabetes to receive monthly injections of the drug, or placebo, plus twice monthly visits with a registered dietitian.

"Neither group really changed their diet" or met their goal of a 500 calorie/day deficit, Coleman reported.

However, at 48 weeks, on average, patients in the treated group had a 21% drop in body fat mass (-7.5 kg, or -16.5 lb), a 6.5% reduction (-5.9 kg) in body weight, and a 3.6% increase (1.7 kg) in lean body mass.

In the placebo group, patients had a 0.5% drop in body fat mass (-0.2 kg), a 0.8% fall in body weight (-0.8 kg), and a loss of lean body mass of 0.8% (-0.4 kg).

Invited to comment, session chair Lee M. Kaplan, MD, PhD, president of the Obesity Society, pointed out that by gaining lean muscle mass, the participants receiving bimagrumab were also losing more fat mass, with the resulting net weight loss of 6.5%, which is similar to that seen with other anti-obesity medications that suppress appetite.

"What it suggests," Kaplan told Medscape Medical News, "is that there may be a completely new mechanism at play here, because in this situation, patients weren't eating less but [those taking bimagrumab]were losing the same amount of weight as [those taking] other drugs that work by causing patients to eat less."

"Is this going to be the kind of complementary drug with a different mechanism that's going to augment the effects of other drugs?" wondered Kaplan, the director of the Obesity, Metabolism & Nutrition Institute at Massachusetts General Hospital in Boston. He was not involved in the current study but has previously served as a scientific consultant to Novartis.

Research is suggesting that there are "multiple subtypes of obesity, like cancer," he added, saying he believes what will eventually be required are "multiple drugs with multiple mechanisms, for multiple subtypes of obesity."

Coleman told Medscape Medical News: "It's exciting that we were able to achieve this profound weight loss with an increase in lean mass in our subjects, along with metabolic benefits."

Coleman explained to delegates that data from a prior phase 2 trial of patients with sarcopenia showed that bimagrumab increased lean muscle mass, but this did not translate into an improvement in function which had been the primary efficacy endpoint of the study so Novartis stopped work on that indication.

Researchers had observed, however, that the drug decreased fat mass in humans, an effect which had not been seen in animal studies.

To further investigate this, researchers first performed a study in 16 patients with prediabetes, which showed that bimagrumab reduced body fat.

Building on this, the current phase 2 study aimed to determine the safety and efficacy of bimagrumab on body composition and glycemic control in adults with obesity and type 2 diabetes.

The investigators enrolled 75 patients who had a BMI of 28 to 40 kg/m2, and an A1c of 6.5% to 10% at 8 sites in the UK and 1 site in the US.

Most patients were were receiving metformin (85%), some metformin plus a DPP-4 inhibitor (4%), while 11% were not on any antidiabetic medication.

Patients in both the bimagrumab and placebo groups had a mean age of about 60 and a mean A1c of about 8%.

However, there were more women in the bimagrumab group than in the placebo group (62% vs 32%) and they had a lower mean weight (90.1 kg vs 98.9 kg) and BMI (32.7 vs 33.1), both of which were adjusted for in the subsequent calculations.

In addition to the frequent visits with a dietitian, all patients were advised to follow a walking program as recommended by the American Diabetes Association.

The patients received subcutaneous injections of 10 mg/kg bimagrumab or placebo every 4 weeks, for 48 weeks, with the last dose at week 44.

Adverse events were primarily mild (such as diarrhea) and transient, and most occurred with the early doses.

At 48 weeks, 96% of the patients receiving bimagrumab had lost at least 5% of their total body fat, and 77% had lost at least 15% of their total body fat.

In terms of weight loss, 66% of those on the active drug had lost at least 5% of their total body weight and 12% had lost at least 15% of their body weight.

A1c was decreased by 0.76% in the bimagrumab group vs 0.04% in the placebo group.

And this despite the fact that those "in the placebo group received more than standard of care," Coleman stressed.

"Nobody's insurance pays for a dietitian every 2 weeks for a year," she said,"and the weight loss diet didnt work."

36th ASMBS Annual Meeting at Obesity Week 2019: Presented November 4, 2019.

For more diabetes and endocrinology news, follow us on Twitter and on Facebook

Continued here:
Investigational Drug Promising in Obese Patients With Diabetes - Medscape

Type 2 diabetes causes the body not to respond to insulin properly, and it may not produce enough, which leads to blood sugar levels becoming too high. If the condition is left untreated, a number of problems can occur, including kidney failure, nerve damage, heart disease and stroke, so doing what you can to control blood sugar levels and prevent the condition is very important.

Regularly eating a poor diet is one of the risk factors for developing type 2 diabetes, so making changes to the food you eat is recommended.

The NHS says theres nothing you cannot eat if you have type 2 diabetes, but certain foods should be limited.

It states: Eat a wide range of foods - including fruit, vegetables and some starchy foods like pasta, keep sugar, fat and salt to a minimum, and eat breakfast, lunch and dinner every day - do not skip meals.

But individual food and drink have also been found to hold blood sugar lowering properties.

READ MORE:Type 2 diabetes: The simple lifestyle change to put the condition in remission

One food which has become increasingly popular to have at breakfast and been shown to prevent diabetes is avocado.

Researchers have shown how a compound found only in avocados can inhibit cellular processes int he pancreas that normally lead to diabetes.

Commenting on the research, Dr Sarah Brewer, whos on the CuraLife advisory board, said: While avocado is often thought of as a vegetable, it is in fact a fruit. Unlike most other fruit, avocados are low in sugar and rich in oils.

As much as 30 percent of the weight of avocado pulp consists of oils, of which 80 percent are beneficial monounsaturated fats similar to those found in olive oil. Although they have a high energy content, avocados also have one of the highest protein content of any fruit.

DON'T MISS

Many people avoid eating avocados because of their high fat and calorie content.

But Dr Brewer advised: But they can aid weight loss and are beneficial if you have diabetes.

The main sugar found in avocado is a unique form known as D-mannopheptulose which does not act like a conventional sugar. It helps to satisfy sensations of hunger and supports improved blood glucose control and weight management.

Together with their protein content, avocados are particularly filling so you tend to eat less overall.

The monounsaturated fat content of avocado also has benefits for glucose control. Research shows that replacing a low-fat, complex-carbohydrate rich diet with an avocado-rich diet can significantly improve blood glucose levels in people with type 2 diabetes.

The research from the University of Guelph suggests avocado may even protect against type 2 diabetes by inhibiting some of the abnormal cell metabolic processes that occur in diabetes.

Dr Brewer explained more about the findings: A particular molecule that is unique to avocados, and known as avocatin B can reduce insulin resistance in skeletal muscle and pancreas cells.

Healthy volunteers who took avocatin B extracts as a dietary supplement lost some weight while continuing to eat their normal diet, and no safety concerns were highlighted. Trials in people with type 2 diabetes are now planned.

Pharmacists and other healthcare professionals are providing increasing support for people who prefer to take more control over their own health.

And Dr Brewer said healing systems such as Ayurveda, which uses more natural approaches such as herbal medicines, are also increasing in popularity.

She said: Medicine is moving away from the old paradigm of diagnose and treat towards one of self-help and prevent.

Dr Brewer also recommended: The blend of 10 Ayurvedic herbs within CuraLin have a range of beneficial effects on glucose control and metabolism.

As a result, users report that their glucose control quickly improves and, in some cases, normalises within four weeks. Users also report reduced cravings for sweet food, and experience improved energy, sleep and general quality of life.

See original here:
Type 2 diabetes: Eating this fruit for breakfast could lower blood sugar - Express

When a 41-year-old African-Canadian man who enjoyed long bike rides on his fixie and pick-up basketball and whose go-to snack was broccoli buds was diagnosed with type 1 diabetes, it obviously came as a surprise.

Oddly, it was a welcome one.

I really thought I was dying, says Daaki Meade, So, when they told me it was diabetes, I was actually relieved.

Daakis symptoms began in 2016. Suddenly, he found it difficult to lift things, and when he stood up too quickly he got head rushes.

Walking home with groceries, I was finding it difficult to carry the bag, he recalls, I had to stop twice in a two-block radius. I was so tired, and it was so heavy.

Daakis appetite decreased but he was thirsty all the time and urinated frequently. He was anxious, depressed and sleeping a lot. He lost weight rapidly, dropping from 250 to 200 pounds over only a few weeks. Soon he was bedridden.

It really seemed like I could lose him, recalls his fianc, Arlee-Anne Goldson. She called 911.

When the ambulance arrived, Daaki couldnt walk. The paramedics brought him to the Schwartz/Reisman Emergency Centre at Mount Sinai Hospital, where tests revealed his blood sugar levels were four times higher than normal a telltale sign of diabetes.

In fact, it was severe onset type 1 diabetes, a disease that usually presents under the age of 35.

Daaki was admitted to the Intensive Care Unit while his care team assessed the disease.

Read more from the original source:
The Changing Face of Diabetes - yorkregion.com

AMA recently published a detailed study of over 180+ pages in its repository on Neuropathy Pain Treatment market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Pfizer [United States], Depomed [United States], Eli Lilly [United States], Endo [Ireland], Grnenthal Group [Germany], Arbor Pharmaceuticals [United States], Astellas Pharma Inc. [Japan], Biogen Inc. [United States], Baxter Healthcare Corporation [United States], Sanofi S.A [France], Abbott Laboratories [United States], AstraZeneca [United Kingdom], Johnson & Johnson Services Inc. [United States], GlaxoSmithKline plc [United Kingdom], Depomed Inc. [United States].

Neuropathy pain treatment involves cure of pain associated with somatosensory nervous system. As of 2018 data, 18% of Canadian population, 7% of French and over 4% of United Kingdom population experience pain of neuropathic origin. With growing geriatric population across the world, the number of neuropathic pain causing diseases will increase significantly, thus, giving pain treatment services offering companies an opportunity to explore in untapped market.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/32655-global-neuropathy-pain-treatment-market

Market Segmentation

by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain, Others), Indication Type (Diabetic Neuropathy, Trigeminal Neuralgia, Post-herpetic Neuralgia, Chemotherapy-induced Peripheral Neuropathy, Others.), Treatment (Medication, Multimodal Therapy), Distribution Channels (Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Research Organizations), Diagnosis (Imaging, Blood Tests)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/32655-global-neuropathy-pain-treatment-market

Whats Trending in Market:

Increasing Demand of Generic Drugs

Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others

Growth Drivers: Rising Geriatrics Population Across the World

Growing Number of Cancer and Diabetes Cases

Restraints: High Cost of Neuropathy Pain Treatment

Lack of Health Infrastructure and Budgets in Emerging Countries

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/32655-global-neuropathy-pain-treatment-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Neuropathy Pain Treatment market study @ USD 2000

And, Europe Neuropathy Pain Treatment market study @ USD 2500

Strategic Points Covered in Table of Content of Global Neuropathy Pain Treatment Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Neuropathy Pain Treatment market

Chapter 2: Exclusive Summary the basic information of the Neuropathy Pain Treatment Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Neuropathy Pain Treatment

Chapter 4: Presenting the Neuropathy Pain Treatment Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Neuropathy Pain Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=32655

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Go here to see the original:

Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description

Rising Prevalence of Cancer Worldwide to Promote Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth

A painful dysfunction of the somatosensory nervous system in the body is called chemotherapy-induced peripheral neuropathy or CIPN. It is estimated that chemotherapy-induced peripheral neuropathy affects an estimate of 68.0% patients who undergo within their first month of diagnosis, among which 30% patients are affected on a chronic basis. The rising prevalence of chronic diseases is promoting the growth of Chemotherapy Induced Peripheral Neuropathy Treatment market. According to Fortune Business Insights, the market for Chemotherapy Induced Peripheral Neuropathy Treatment is anticipated to rise exponentially with increasing prevalence of diabetes worldwide.

Browse Complete Report [emailprotected] https://www.fortunebusinessinsights.com/industry-reports/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Rising Prevalence of Cancer to Help Generate High Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenues

The increasing prevalence of chronic diseases such as diabetes and cancer are the major factors promoting the Chemotherapy Induced Peripheral Neuropathy Treatment market. The surge in adoption of chemotherapy is significantly helping to increase the prevalence of peripheral neuropathy. Additionally, lack of proper guidelines about chemotherapy heightens the chance of additional incidence of peripheral neuropathy. This is expected to bode well for generating greater percentages of the global Chemotherapy Induced Peripheral Neuropathy Treatment market share.

However, the market may face certain challenges in terms of the lack of awareness about symptoms of chemotherapy-induced peripheral diagnosis, especially in developing nations. Such challenges may hamper the global Chemotherapy Induced Peripheral Neuropathy Treatment market growth in the forecast period.

Get PDF Brochure of this [emailprotected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Some of the companies operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market include:

Improving Healthcare Infrastructure and Medical Facilities of Developing Nations to Help Asia Pacific Market Grow Significantly

According to the Center for Diseases Control and Prevention (CDC), ABOUT 1,633,390 new cancer cases were reported in the U.S. in 2015, among which, an estimated 595,919 people died of cancer. As per the geographical categorization, North America is currently holding a significant share in the global Chemotherapy Induced Peripheral Neuropathy Treatment market and is anticipated to continue doing the same in the forecast period as well. This is attributable to the rising prevalence of cancer which is further propelling the demand for chemotherapy treatment by patients and their family members.

On the other side, the global Chemotherapy Induced Peripheral Neuropathy Treatment market in Asia Pacific and Europe will also witness remarkable growth rate during the forecast period owing to improving healthcare infrastructure and medical facilities, especially in the developing nations.

Strategic Partnerships to Help Market Players Gain Strong Foothold in Market

As per the report, the global Chemotherapy Induced Peripheral Neuropathy Treatment market highlights some of the major market shareholders significantly driving the market. These companies are mentioned below

Manufactures continue to focus on new product launches and merger and acquisition strategies to increase their customer base and broaden product portfolio. These manufacturers produce new therapeutic methods to maintain a strong foothold in the market. Some of the recent development made by companies are mentioned below

More Trending Topics From Fortune Business [emailprotected]

U.S. Biosimilars Market 2019 Global Technology, Consumption, Segmentation, Growth, Development, Trends and forecasts to 2026

Mass Spectrometer Market Size Overview by Share, Growth Factor, Industry Trends, and Analysis to 2026

About Us

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune Business Insights

The rest is here:

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune...

The Global Neuropathy Pain Treatment Market is the increasing incidence of neuropathic pain caused by damage or

disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth

Buy one-Get one: https://www.orianresearch.com/checkout/956157

[Buy this report and get another report of the same price for free. offer for limited period only].

Based on type, the market is divided into:

Based on application, the market is divided into:

Moreover, the market is classified based on regions and countries as follows:

For More Info, Get Sample Report Here @ https://www.orianresearch.com/request-sample/956157

Key Market Players:

Key Benefits of the Report:

Target Audience:

GET Flat 40% Discount https://www.orianresearch.com/discount/956157

[Avail flat 40% discount on this report. offer for limited period only]

Table of Contents

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com

See the original post:

Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast...

Diabetic Peripheral NeuropathyMarket

Diabetic PeripheralNeuropathy-Epidemiology Forecasting Intelligence report provides acomprehensive analysis of the Diabetic Peripheral Neuropathy epidemiology,providing the historical, current, and forecasted data for the United States,European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) andJapan during the period from 2018-2028.

Our epidemiology services include:

Incidence andprevalence Diagnosis rate, treatment rate and mortality patterns Epidemiology-based forecasting and disease trends Size of different patient segments in a disease area Population based: disease occurrence, co-morbidities and treatment patterns Geographic Regional Ethnic differences

Along with the epidemiological data, the reportalso includes:

Disease overview,causes, symptoms, classification, risk factor, pathophysiology, diagnosis andtreatment Patient treatment journey Treatment algorithm and guidelines Assesses the disease risk and burden Highlights the unmet needs Market driver and barrier Growth opportunities and market trend analysis

Methodology

This report isbuilt using data and information sourced from proprietary databases, primaryand secondary research and in-house Epidemiology Forecast model analysis by ateam of industry experts. To generate accurate patient population estimates, utilizes a combination ofseveral world class sources that deliver the most up to date information frompatient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have beenidentified in the report.

Note:

Systematic review ofthe epidemiological literature is also provided for full transparency intoresearch and methods. This report can be delivered to the clients within 4-5business days.

Request customize:-

If you wish to find more details ofthe report or want a CustomizationPlease contacts us. You can get adetailed of the entire research here.

Ozone Market Reports is committed towards delivering intensiveresearch based analysis reports, enabling clients to easily make fact-baseddecisions. We also have with us the facility of our innovatively designed anddeveloped data processing and analysis division.

Ozone Market Reports is a research-based consulting firmspecializing in getting research inputs and using them appropriately in themarketing planning process. In saying this, we are trying to convey that wealways attempt to interpret the research data from the viewpoint ofrecommending action priorities both short-term and long-term. To this end, wehave put together a team that understands not only research techniques, butalso branding concepts in depth.We believe our people are our clientsbiggest assetshence we do our best to recruit multi-skilled individuals,and then give them an environment where they can think and ideate freely.

We offer various services for our clients to help them choosewhats most relevant and best for them required for their business.

Contact Us:

Name: Steven Samuel

Email info@ozonemarketreports.com

Phone +91 9370882135

Website: https://www.ozonemarketreports.com/

Post Views: 70

Read the original post:

Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal

For patients with diabetes, cardiovascular disease should be a top priority.

Nathan D. Wong, PhD, director of the Heart Disease Prevention Program at the University of California, Irvine, is a co-author of the Heart Disease and Diabetes chapter in the NIDDK publication Diabetes in America, 3rd Edition. Here he talks about the importance of broadening the clinical focus of diabetes care from hemoglobin A1C to also include other risk factors for cardiovascular disease common in patients with diabetes.

Q: Why is it so important to talk about heart disease with patients who have diabetes?

A:More than two-thirds of patients with diabetes will die of cardiovascular-related illnesses such as coronary heart disease, stroke, heart failure, and peripheral arterial disease. For women with diabetes, the risks for different forms of cardiovascular disease are three to seven times greater compared with women who do not have diabetes. For men with diabetes, the risk is two to three times greater.

We are doing a poor job of managing heart disease in people with diabetes in this country and throughout the world, despite many advances in therapies over the past 30 years. We still have a very small percentage of people with diabetesfewer than one in fivewho meet appropriate targets for hemoglobin A1C, blood pressure, and LDL cholesterol; even fewer additionally meet the recommendations for physical activity, a healthy diet, nonsmoking status, and body mass index.

Many of these factors have an impact on risk for certain microvascular complications associated with diabetes such asretinopathy, nephropathy, and neuropathy. But these factors also affect risk for macrovascular complications such as heart disease and stroke.

Q: How does cardiovascular risk differ for type 1 and type 2 diabetes?

A:When people are diagnosed with type 2 diabetes, they often already have hypertension and dyslipidemia. For people with type 1 diabetes, the diagnosis generally comes when theyre much younger, so they arent yet at significant cardiovascular risk. Theres a true opportunity to help prevent them from developing cardiovascular risks in the first place, rather than trying to catch up with these factors after theyve developed and are more difficult to control.

Q: What are the benefits of keeping all the cardiovascular risk factors at target levels?

A: The Steno 2 clinical trial found a 53% risk reduction in cardiovascular outcomes for people with type 2 diabetes who were intensively treated for risk factors, compared with participants in the control group. In a follow-up paper, the researchers reported on mortality rates after 13 years. They found it was significantly lower for the intensively treated group. Just 30% had died, compared with 50% of the conventionally treated group.

In an observational study, we pooled data on people with diabetes from three different clinical trials to show an approximately 60% lower risk for developing coronary heart disease or cardiovascular disease in people with diabetes who were at target levels for LDL cholesterol, blood pressure, and hemoglobin A1C. This suggests we can possibly reduce the risk of future heart attacks or strokes by more than half, if we ensure that these factors are controlled.

Q: What does this mean for diabetes care?

A:We still have a lot of work to do to get the word out that diabetes is really a cardiovascular condition. Most people with diabetes are not dying from retinopathy or neuropathy; they are dying from cardiovascular disease. This is not to trivialize the microvascular complications. Obviously, neuropathy or retinopathy can significantly affect quality of life. But in terms of what a person with diabetes eventually will die of, its cardiovascular disease. Patients and their health care providers really have to better understand that controlling diabetes is much more than controlling blood sugar.

Certainly, managing glucose is critical to prevent microvascular complications, in particular. There is strong epidemiologic data that adverse cardiovascular outcomes are greater in people with higher levels of hemoglobin A1C, but the evidence is less striking for improving cardiovascular outcomes from glucose control alone. And in fact, the ACCORD trialactually showed increased cardiovascular mortality to occur when targets were set too aggressively for hemoglobin A1C.

Q: How can the message on cardiovascular risk factors reach more health care professionals?

A:I think theres tremendous opportunity to advance professional education to help improve cardiovascular outcomes in people with diabetes. And this, of course, can be accomplished with lifestyle changes. But few people with diabetes see a dietician and/or exercise physiologist as frequently as they should to help them with theirdiabetes self-management. These allied health care providers are not traditionally part of the health care team as much as they should be, because reimbursement is not always available for their services. Physicians need to know that these resources exist, and that they can also prescribe lifestyle improvements such as walking or eating more vegetables.

At professional meetings, I've asked for a raise of hands: How many of you physicians have heard of the American Medical Association? Virtually all of them have. Then I ask, How many of you have heard of theAcademy of Nutrition and Dietetics? Very few have, yet this is a very powerful group. Specifically, the Academys Sports, Cardiovascular and Wellness Nutrition dietetic practice group includes close to 10,000 people around the country. The American College of Sports Medicine includes exercise physiologists. But there's a disconnect. We need to help physicians know that these other providers, who are key to patients success in managing their diabetes and cardiovascular risks, exist.

Q: How can cardiologists contribute to better care for patients with diabetes?

A:The American College of Cardiology advocates for cardiologists to learn more about how to manage diabetes. This is largely fueled by the fact that we now have newer medications that are shown to reduce cardiovascular events in people with diabetes. These drugs are not the most powerful A1C-lowering agents, but theyre the only agents shown to have benefits in terms of cardiovascular outcomes. The sodium-glucose cotransporter-2 (SGLT2) inhibitors, in particular, have the dramatic effect of reducing heart failure-related hospital stays by more than 30%. Equally exciting are the glucagon-like peptide-1 (GLP-1) receptor agonists, which seem to have more of an anti-atherosclerotic effect.

Both of these therapies have been incorporated into several guidelines. The American College of Cardiology, the American Association of Clinical Endocrinologists, the American Diabetes Association, and the American Heart Association recommend these therapies specifically for people with pre-existing diabetes and cardiovascular disease.

But its mainly the specialty community that has started to use these therapies. We need to increase efforts to communicate the value and the indications of these therapies among primary care providers, too.

Q: What advice do you have for health care professionals so that they can better help their patients with diabetes manage the cardiovascular risk factors?

A:Providers and patients with diabetes alike need to understand that cardiovascular disease should be their main concern. It takes a concerted approach to manage all the relevant risk factors to significantly improve outcomes. Were talking about a multidisciplinary cardio-diabetes care team that includes lifestyle specialistsdieticians and physical activity expertsas well as other appropriate specialists, including the endocrinologist and the cardiologist, and, in many cases, the primary care provider at the center of the patients care.

Health care professionals also need to motivate patients to take greater charge in their health care.Shared decision-making is very important in starting new therapies and managing lifestyle changes.

What has been your experience addressing cardiovascular risk in your patients with diabetes? Tell us below in the comments.

Follow this link:

Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Key Point: the Russian military will be using genetics to assess that most unpredictable of human qualities: how a person will react in combat.

Want to be a Russian paratrooper or tank commander? Then youd better hope you have the right genes.

The Russian military will be assigning soldiers based on their genetic passports.

The project is far-reaching, scientific, fundamental, Alexander Sergeyev, the chief of Russias Academy of Sciences, told Russian news agency TASS back in the summer (English translation here). Its essence is to find such genetic predispositions among military personnel, which will allow them to be properly oriented according to military specialties.

It is a question of understanding at the genetic level who is more prone to, for example, to service in the fleet, who may be more prepared to become a paratrooper or a tankman.

Advances in medical technology are making genetic testing a common medical procedure. It is used to detect genetic diseases such as cystic fibrosis, or the risk of developing certain diseases such as colorectal cancer. Pregnant women can also choose to be tested to determine whether their baby has genetic abnormalities such as Down syndrome.

But Russian President Vladimir Putin has embraced genetics with a passion. In March, the Kremlin issued a decree that called for implementation of genetic certification of the population, taking into account the legal framework for the protection of data on the personal human genome and the formation of the genetic profile of the population. Ostensibly this is to protect Russias population against chemical and biological attack, as well as safeguard Russias genetic patrimony from Western spies and saboteurs.

It has also spurred fears that Russia is edging towards a Nazi-style eugenics program in which certain groups, such as those Russians of Slavic ancestry, will be favored.

Either way, the Russian military will be using genetics to assess that most unpredictable of human qualities: how a person will react in combat. The project involves not only the assessment of the physiological state, but also the prediction of human behavior in stressful, critical situations that are associated with the military profession, says Sergeyev, Russia's chief scientist. Resistance to stress, the ability to perform physical and mental operations under the conditions of this stress, and so onall this may be contained in a soldiers genetic passport.

It is not just soldiers who will be genetically profiled. In December 2018, another Russian scientist announced that cosmonauts will be tested. The first area is the research into the humans genetics from the viewpoint of using it in the selection [for the cosmonaut program], said Lyudmila Buravkova, deputy director of the Institute of Medical and Biological Problems at the Russian Academy of Sciences. The second area is the attempt to remedy genetic errors as much as this should be done before a flight.

To be clear, many militaries use some kind of testing, such as the U.S. militarys Armed Services Vocational Aptitude Battery (ASVAB), to determine whether someone is qualified for military service, and whether they are suitable for certain positions such as technical jobs. The U.S. military collects DNA from soldiers to identify their bodies if they are killed. The Defense Health Agency told the National Interest that the U.S. military does not use genetic testing to assign personnel.

Thats not surprising, given that genetic testing would certainly raise concerns over privacy and racial profiling. A civil rights issue that isnt likely to be a cause of furor in an authoritarian society like Russia.

The bigger question is whether an army can decide whether someone is better suited to be a pilot, a rifleman or a cook based on their genetic profile.

Michael Peck is a contributing writer for the National Interest. He can be found on Twitter and Facebook.

Read more:
The Russian Military Will Soon Assign Soldiers Based on Their "Genetic Passports" - The National Interest Online

Scientists at the Max Planck Institute of Psychiatry in Munich, Germany, together with colleagues at the Weizmann Institute of Sciencein Israel have developed a computational method to objectively measure the personality of mice living in a semi-natural, group environment.

Just like humans, every mouse is different. Some are quick to explore a new environment while others prefer to stay within the comfort of their nest. Some prefer to stay close to their cage-mates, while others prefer to be alone. These unique characteristics of an individual remain fairly stable through life and define their personality. In humans, personality can be measured using multiple-choice questionnaires to derive personality scores but how can one measure personality in animals?

Oren Forkosh and Stoyo Karamihalev, together with other colleagues collected huge amounts of data by analyzing video footage taken of groups of mice. To do this, they dyed the fur of each mouse a different color allowing them to track the groups of mice behaving undisturbed. Each video was analyzed for a repertoire of 60 behaviors, such as how close a mouse stays to other mice, if they chase one another or run away, or the time spent in the nest or eating.

Some mice are curious and explore every new hiding place. Others are more anxious and prefer to stay in their nest. Credit: MPI f. Molecular Genetics

The scientists developed a mathematical algorithm that sought stable traits that were able to discriminate individuals based on differences in behavior. This method works somewhat in the same way as personality tests in humans in which people are often assessed on five dimensions, however, it specifically searches for traits that are consistent over time. In mice, the algorithm identified four trait-like dimensions that could capture and describe the behavior of mice. To test that these traits were stable, the researchers mixed up the groups and found that while some of the behaviors had changed, the personalities of the mice were still stable. Using advanced RNA-sequencing tools and genetically modified mouse strains, the researchers were also able to show that individual differences captured in these traits corresponded to a variety of differences in gene expression in the mouse brain and could identify mice with different genetic makeup.

This method has the potential to greatly advance our knowledge beyond what is possible using the current simplified methods for assessing behavior and toward stable and consistent differences in personality. It opens up the possibility to study how personality is affected by genes, drugs, aging, etc., how it is represented and maintained by the brain, and how it contributes to mental health and disease, explains Karamihalev, together with Oren Forkosh one of the first authors of the study published in Nature Neuroscience. This is a good first step in the direction of better pre-clinical methods for assessing individual differences in behavior and physiology, says Alon Chen, the principal investigator for this study. Our hope is that such approaches will aid in the effort toward a more personalized psychiatry.

Reference: Identity domains capture individual differences from across the behavioral repertoire by Oren Forkosh, Stoyo Karamihalev, Simone Roeh, Uri Alon, Sergey Anpilov, Chadi Touma, Markus Nussbaumer, Cornelia Flachskamm, Paul M. Kaplick, Yair Shemesh and Alon Chen, 4 November 2019, Nature Neuroscience.DOI: 10.1038/s41593-019-0516-y

Continue reading here:
Scientists Measure Mouse Personality and Map Traits to Their Genetics - SciTechDaily

Identifying the best genetics within a Merino flocks variation will sort out the massive difference between the top and bottom performers, according to the Australian Merino Sire Evaluation Association.

In terms of profitability, AMSEA has identified that the top 25 per cent performers of a flock would make $31 per ewe per year more than the bottom 25 per cent.

AMSEA was founded in 2000 to oversee and create policy for all sire evaluation trials in Australia, through a national committee.

Sorting the most profitable Merino genetics was the hot topic at the Department of Primary Industries and Regional Developments Science of the Merino Sheep Field Day at Katanning last Tuesday, November 29.

The event attracted 35 visitors to DPIRDs Katanning Research Facility, including woolgrower participants, researchers and industry representatives who had a first-hand glimpse of the Yardstick Merino Sire Evaluation Trial.

AMSEA executive officer Ben Swain welcomed participants to the trial, which was established in 1989 to compare the breeding performance of Merino sires by evaluating their progeny.

A consistent ewe base is joined to trial sires via an artificial insemination program, and the resulting progeny are evaluated to assess a sires breeding performance for a large number of traits, which are important to breeders and commercial producers, he said.

The results assist in the selection of sires suitable for a large range of breeding objectives.

Mr Swain said Yardstick was one of 10 active Merino sire evaluation sites located across Australia.

Yardstick works to breed sheep that are to be well-grown and structurally sound, he said.

There needs to be a balance between wool and body size in order to provide the typical dual-purpose WA Merino type.

Mr Swain said typically, when run commercially, a Merino ewes body weight would be 10 times the greasy fleece weight.

Visually, the wool should be medium length, of attractive crimp, bright and white, uniform over the body and with no evidence of fleece rot, he said.

Head and hock cover is of little importance.

Mr Swain said there were 5000 different businesses influencing ram genetics across Australia, including 1000 stud Merino breeders and 4000 commercial woolgrowers.

We estimate 22 per cent of commercial woolgrowers breed their own rams, bringing to the fore of why it is important to use Yardstick analysis as a profitability incentive, he said.

Scaddan stud Merino breeder David Vandenberghe, of Wattle Dale stud, had two sires progeny groups in the Yardstick trial at the field day.

He said through his participation in MerinoSelect and the trial, he was able to identify a 2018-drop ram which was a multiple trait leader.

From the Merinoselects animal ID website, Wattle Dale 182067 recorded 10 trait leading measurements including 14.3 YWT, 35.5 YCFW, 21.2 ACFW, -2.3 YFD, plus all six indexes including a DP+ of 212.

We will enter this ram in Yardstick and will be anxious to see how its progeny will perform in due process, Mr Vandenberghe said.

Read the original here:
Science of the Merino day shines light on genetics - The West Australian

Nov. 12, 2019 14:00 UTC

LOS ALTOS, Calif. & FAIRFIELD, Calif.--(BUSINESS WIRE)-- GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, announced today that NorthBay Healthcare, an independent nonprofit health system in Northern California, has selected the GenomeBrain Platform for a pilot program planned to improve the routine use of genetic testing in patient care.

Weve looked at many options to support our providers but the GenomeBrain Platform offered us more of the critical features we wanted plus gave us the ability to customize to our needs, said Lori Muir, Oncology Services Director. NorthBay Healthcare is dedicated to delivering best-in-class oncology care to the patients we serve and we believe ensuring easy access to genetic testing is a critical part of those vital services. Were looking forward to working with GenomeSmart to support our providers in better identifying patients for testing, efficiently tracking available tests, and speeding access to hereditary risk results.

"This approach to screening patients will make it much easier for people to understand why and when genetic testing can impact their healthcare decisions. We are bridging an educational gap that, until now, has made access to genetic testing difficult. Our patients will no longer wonder if genetic testing is right for themthey will know before they even come in to see me," added Karen Vikstrom, MS, Certified Genetic Counselor, NorthBay Healthcare.

The NorthBay Healthcare pilot program will be completed in conjunction with the NorthBay Breast Cancer Program. The pilot is designed to ensure patients with breast cancer receive treatment based on genetic risk and to scale testing into routine care for healthy women and men to identify potential hereditary risks, ensuring appropriate access to screening and care programs. The GenomeBrain Platform will be incorporated into the current patient workflow and evaluated for effectiveness and ease of use.

The GenomeBrain Platform is accessed online through a mobile phone, tablet, or desktop device. The simplified experience first builds a patient profile, including their relevant personal medical history, family medical history, ethnicity and age, and then instantly matches them to the appropriate genetic tests based on the latest medical guidelines for genetic testing. GenomeBrain uses AI to ingest large amounts of data from patient history, genetic tests available on the market, and medical guidelines to simplify a cumbersome manual process that usually takes days to less than ten minutes on average.

Were thrilled to be partnering with NorthBay Healthcare on this important initiative, said Sanjay Sathe, CEO and co-founder, GenomeSmart. The NorthBay teams agility and interest in innovative approaches to care make them the ideal partner for us. They are able to implement efforts quickly and provide personalized care to their local community that rivals many larger urban-based institutions, all for the betterment of their patients.

About GenomeSmart

GenomeSmart is on a mission to make genetic testing available to everyone. In May 2019, the company launched GenomeBrain, the first and only AI-powered genetic risk assessment and test recommendation platform that matches and identifies people who could benefit from genetic testing. The affordable GenomeBrain Platform multi-functional solution is available to help genetic counselors, physicians, hospital systems, genetic testing labs, insurance companies, and corporations improve the effective use of genetic testing to save lives, improve quality and reduce costs of healthcare.

About NorthBay Healthcare

NorthBay Healthcare opened its first hospital in 1960 and remains Solano Countys only locally based, locally managed nonprofit health system. NorthBay Medical Center in Fairfield and NorthBay VacaValley Hospital in Vacaville offer 24-hour emergency care, intensive care, and sophisticated surgical and diagnostic services. NorthBay Cancer Center, located on the Vacaville campus, opened more than 30 years ago. NorthBay Healthcare is a member of the Mayo Clinic Care Network, giving its patients access to world-renowned physicians and Mayo Clinic research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005437/en/

See the original post:
GenomeSmart and NorthBay Healthcare Launch Pilot to Improve Access to Genetic Testing with GenomeBrain - BioSpace

Since Invitaes inception a decade ago, the firm has been working for the proactive use of genetic information in mainstream medicine. The San Francisco, CA-based company has been using M&A activity to help bring companies under its tent to help make this goal a reality.

On Monday, the genetic-testing specialist made more progress on this front by announcing it would put down $50 million to acquire Clear Genetics, a company that develops digital counseling software.

San Francisco, CA-based Clear Genetics has developed Gia, a chatbot that equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results.

Invitae said Gia can guide patients regarding consent, personalized risk assessment, insurance benefits, pre/post-test education and understanding their test results, all through an intuitive online conversation. Patients are able to ask Gia questions throughout the process, and the chatbox uses natural language processing to respond with the resources they need. Gia is currently being used by customers in Invitae's direct channel.

In a release, Sean George, co-founder and CEO of Invitae said, For genetics to truly go mainstream, patients and clinicians need automated workflow solutions like those Clear Genetics has created. In working with the Clear Genetics team over the past year, we have first-hand experience with the value of their patient-centric services. With their capabilities, we will greatly enhance our ability to provide a streamlined customer experience, enable scaled clinician education and support, and arm genetics experts with the tools they need to keep up with the exploding demand for genetic information in healthcare.

Taking genetics mainstream is a lofty goal, but through a wide range of acquisitions, Invitae is quickly accomplishing this task. Just a few months ago the company reported it signed an agreement to acquire Singular Bio, a non-invasive prenatal screening (NIPS) specialist for $55 million.

Two years ago, Invitae landed two deals acquiring both Good Start Genetics and CombiMatrix, two companies that specialize in screening prospective parents and newborns. During a 2017 earnings call discussing the deals, George said these acquisitions were the beginning of genetics being broadly available to all and accessible to all in mainstream medicine.

Invitaes 3Q19 earnings paint the picture the companys strategy is significant inroads in reaching this goal. Looking at the numbers, the company generated revenue of $57. million in 3Q19, which represented a 51% increase over 3Q18 revenue of $37.4 million.

Ten years ago, when we started Invitae [we wanted] to get genetic information incorporated into mainstream medical use for everyone around the world in modernized economies, George said during Invitaes 3Q19 earnings call, according to a Seeking Alpha Transcript. While we have many years to go, the transformation of the genetics industry is underway. And we believe our 26th quarter of on average double-digit quarter-over-quarter growth serves as an indication of a new trajectory, a new model for personalized medicine as we move this industry beyond the more than 1.7 million people in the U.S. diagnosed with cancer per year into all of the equally impactful genetic disorders affecting those we serve.

Read the rest here:
Deal Helps Bring Genetic Information to Mainstream Medicine - Medical Device and Diagnostics Industry

If certain vegetables have always made you gag, you may be more than a picky eater. Instead, you might be what scientists call a super-taster: a person with a genetic predisposition to taste food differently.

Unfortunately, being a super-taster doesnt make everything taste better. In fact, it can do the opposite.

Super-tasters are extremely sensitive to bitterness, a common characteristic of many dark green, leafy veggies such as broccoli, cauliflower, cabbage and Brussels sprouts, to name a few.

The person who has that genetic propensity gets more of the sulfur flavor of, say, Brussels sprouts, especially if theyve been overcooked, said University of Connecticut professor Valerie Duffy, an expert in the study of food taste, preference and consumption.

So that [bitter] vegetable is disliked, and because people generalize, soon all vegetables are disliked, Duffy said. If you ask people, Do you like vegetables? They dont usually say, Oh yeah, I dont like this, but I like these others. People tend to either like vegetables or not.

In fact, people with the bitter gene are 2.6 times more likely to eat fewer vegetables than people who do not have that gene, according to a new study presented Monday at the annual meeting of the American Heart Association.

We wanted to know if genetics affected the ability of people who need to eat heart-healthy foods from eating them, said study author Jennifer Smith, a registered nurse who is a postdoc in cardiovascular science at the University of Kentucky School of Medicine.

While we didnt see results in gene type for sodium, sugar or saturated fat, we did see a difference in vegetables, Smith said, adding that people with the gene tasted a ruin-your-day level of bitterness.

Our sense of taste relies on much more than a gene or two. Receptors on our taste buds are primed to respond to five basic flavors: salty, sweet, sour, bitter and umami, which is a savory flavor created by an amino acid called glutamate (think of mushrooms, soy sauce, broth and aged cheeses).

But its also smelling through the mouth and the touch, texture and temperature of the food, Duffy said. Its very difficult to separate out taste from the rest. So when any of us say the food tastes good, its a composite sensation that were reacting to.

Even our saliva can enter the mix, creating unique ways to experience food.

When we come to the table, we dont perceive the food flavor or the taste of food equally, Duffy said. Some people live in a pastel food world versus others who might live in a more vibrant, neon food world. It could explain some of the differences in our food preference.

While there are more than 25 different taste receptors in our mouth, one in particular has been highly researched: the TAS2R38, which has two variants called AVI and PAV.

About 50% of us inherent one of each, and while we can taste bitter and sweet, we are not especially sensitive to bitter foods.

Another 25% of us are called non-tasters because we received two copies of AVI. Non-tasters arent at all sensitive to bitterness; in fact food might actually be perceived as a bit sweeter.

The last 25% of us have two copies of PAV, which creates the extreme sensitivity to the bitterness some plants develop to keep animals from eating them.

When it comes to bitterness in the veggie family, the worst offenders tend to be cruciferous vegetables, such as broccoli, kale, bok choy, arugula, watercress, collards and cauliflower.

Thats too bad, because they are also full of fiber, low in calories and are nutrient powerhouses. Theyre packed with vitamins A and C and whats called phytonutrients, which are compounds that may help to lower inflammation.

Rejecting cruciferous or any type of vegetable is a problem for the growing waistline and health of America.

As we age as a population, vegetables are very important for helping us maintain our weight, providing all those wonderful nutrients to help us maintain our immune system and lower inflammation to prevent cancer, heart disease and more, Duffy said.

Food scientists are trying to develop ways to reduce the bitterness in veggies, in the hopes we can keep another generation of super-tasters from rejecting vegetables.

Theres been some success. In fact, the Brussels sprouts we eat today are much sweeter than those our parents or grandparents ate. Dutch growers in the 90s searched their seed archives for older, less bitter varieties, then cross-pollinated them with todays higher-yielding varieties.

People who already reject vegetables might try to use various cooking methods that can mask the bitter taste.

Just because somebody carries the two copies of the bitter gene doesnt mean that they cant enjoy vegetables, Duffy said. Cooking techniques such as adding a little fat, a little bit of sweetness, strong flavors like garlic or roasting them in the oven, which brings out natural sweetness, can all enhance the overall flavor or taste of the vegetable and block the bitterness.

More:
Your hatred of heart-healthy veggies could be genetic - WTVR CBS 6 News

The market is estimated to grow with a CAGR of 21. 4% from 2018-2025. The growth of the next generation sequencing market is primarily attributed to the technological advancements in sequencing and an extensive use of genomics for medical applications.

New York, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Next Generation Sequencing Market to 2025 - Regional Analysis and Forecasts by Product; Service; Application; & End User, and Country" - https://www.reportlinker.com/p05794719/?utm_source=GNW However, nonexistence of skilled professionals and high risks associated with genetic data.

On the other hand, an extensive use of genomics for medical applications is likely to have a positive impact on the growth of the Europe next generation sequencing market in the coming years.The genomics is comprised of various technologies such next generation sequencing (NGS), genome editing, gene synthesis and more.These technologies have been utilized for achieving various discoveries for the betterment of the health conditions across the living organisms.

The next generation sequencing is widely used in the field of the medical to understand the genetic composition of the patients.The use of NGS has been utilized for the alteration of plants and animals for the desired physical and genetic changes.

The technology is used to produce biomarkers.The biomarkers are widely used in clinical research and clinical practice.

NGS is among the important developments in genomic technologies, the technology is used for the discovery of oncogenic biomarker and diagnostics. NGS enables in discovery of biomarker and identifying the genetic diseases. In addition, the NGS is used for the developing precision medicine for individuals genomic information to offer targeted treatment to the individual. NGS have capability of sequencing large sections of a persons genome in very short period of time and can also aid in formulation of precision medicine. Next generation sequencing technology is among the major driver of precision medicine and has improved its accuracy, speed, and cost. Developments in whole genome sequencing has enabled the identification of genes required in the large number of diseases, and biomarkers that indicate disease severity to treatment are gradually being characterized. Therefore, the use of the NGS for the discovery of biomarker have benefited for the early diagnosis and differentiating in disease types. Likewise, precision medicine enables in treatment of the diseases NGS plays significant role for both the application by creating an array of opportunities in future.In 2017, the consumables segment held a largest market share of 64.0% of the next generation sequencing market, by product. The segment is growing due to the consumables offered by various companies are widely accepted by the consumers and it provides accuracy and precision in the preparation of the NGS. Furthermore, the similar segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2025.In 2017, the resequencing segment held a largest market share of 66.0% of the next generation sequencing market, by technology. This segment is also expected to dominate the market in 2025 as the rising funding by various government bodies and usage of NGS in the resequencing and targeted sequencing. Furthermore, the genome sequencing segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2025.Diagnostics segment is anticipated to grow at a CAGR of 22.0% during the forecast period owing to the growth of the technological advancements such as sequencing machines in the developed and developing regions. Moreover, the similar segment held the largest market share of 34.0% for the application segment in the next generation sequencing market and is likely to dominate the market in coming forecast period.In 2017, the academic & research institutes segment held a largest market share of 45.2% of the next generation sequencing market, by end user. This segment is also expected to dominate the market in 2025. Moreover, the similar segment is anticipated to witness the fastest growth rate of 21.9% during the forecast period, 2017 to 2025. This higher growth rate of the segment owing to the providing the references for further researches are likely to propel the growth of the research centers segment in the coming future.Some of the major primary and secondary sources for next generation sequencing included in the report are, Non-Invasive Prenatal Testing (NIPT), Food and Drug Administration (FDA), Developing an European - American NGS Network (DEANN), Foreign Direct Investment (FDI) and among others.Read the full report: https://www.reportlinker.com/p05794719/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Follow this link:
The Europe next generation sequencing market is expected to reach US$ 7,685.4 Mn in 2025 from US$ 1,633.4 Mn in 2017 - Yahoo Finance

Extending the Healthy Human Life Span

For millennia, humans have dreamed about extending their lives. Today, medical assessments are available that can impact longevity, identify risks for disease, and provide early diagnosis for serious diseases, including insights into critical areas such as coronary artery disease, neurovascular disease, dementia, cancer, and metabolic disease.

Looking at the past 30 years medical practice, we can see that the physician is the integrator of data: He takes a family history and performs a physical exam and basic blood work to make an assessment of the patients health. The tools are familiar: blood pressure cuff, thermometer, and otoscope (checking ears and nose).

The next generation of medicine has machine learning and artificial intelligence as the integrators of data alongside the physician. Inputs involve more detailed information to analyze current health status, including whole-genome sequencing, whole-body and brain MRI (imaging), and advanced bloodwork, all to reveal a precision, personalized, and integrated look at potential risks as well as immediate issues.

[To read more of Dr.Ram Dandillaya s thought leadership click here]

Measure What Matters

If we compare how we measure and monitor our cars, finances, social media, and a myriad of other aspects of our lives to how often and detailed we measure our health status, we might see where preventive measures might help extend our lives.

Craig Venter co-founded Human Longevity Inc. in 2013 and established the Health Nucleus in 2015, a serene and sophisticated research and discovery center based in La Jolla, Calif. By implementing whole-genome sequencing with whole-body and brain imaging and a full and complete set of blood tests, the health assessment these companies offer is truly data driven. That is, unlike more recreational DNA kits, we believe that the code should be assessed with all 6B base pairs. Its not a superficial exam, but rather a deep assessment integrating all results to achieve one of the most precise and personalized assessments available.

An example of our work may be seen in a recent study soon to be published that reviewed 1,190 healthy clients who visited the Health Nucleus. Many received the peace of mind that they are on track with their health: exercising, maintaining a healthy weight, eating nutritious foods, and finding balance in their lives. We also found that a significant portion actually had findings that required medical attention.

Highlights include:

1.7% confirmed cancers otherwise not previously known

2.5% brain and aortic aneurysms, several of which requiredfollow-upinterventions

7% with moderate to severe cardiovascular risk with significant calcified plaque in the coronary arteries

16% with aberrant cardiac structure or function findings

29% with elevated liver fat, which may indicate a risk for developing type 2 diabetes

86% genetic carriers for recessive diseases

17% have a rare genetic mutation

No longer a dream, assessing ones health in these critical areas is not only extremely pertinent to most people but is especially important for addressing chronic, age-related diseases, many of which may be positively impacted by behavior changes, including changes in diet and lifestyle.

On staff at Health Nucleus as chief medical officer is Thomas Caskey, MD, FACP, FACMG, FRSC. A world-renowned expert in clinical genetics, he is part of the team that reviews genetic data and offers advice to our clients through our genetic counselors and medical team. Dr. David Karow serves as president and chief innovation officer and has published numerous papers on early prostate cancer detection through noninvasive, advanced MRI. More recently, he has focused on integrating imaging and genomic biomarkers for identifying disease risk long before disease onset. Recommendations from functional medicine physicians, especially when it comes to taking next steps in improving health, are also important future attributes for the Health Nucleus assessment.

As a cardiologist, my practice Atelier Health is based in Beverly Hills and I have adopted the Health Nucleus protocol with my patients. Using the same testing, I access MRI technology locally, and the Health Nucleus provides the blood, genetic, and image integration to produce a Health Intelligence Report, which I deliver to my patients approximately six weeks after the initial assessment, during a return-of-results session in my office. One of the reasons I am looking forward to providing this assessment to my clients is found in reviewing past client experiences at the Health Nucleus facility. Three in particular show the benefits of how this early assessment provides benefits from peace of mind, from revealing genetic predisposition to early diagnosis of cancer.

One client, Nick B. credits forward-thinking technologists, medical professionals, and scientists who are creating a 21st century approach to healthcare. Human Longevity, through their Health Nucleus assessment, gave me access to the technologies required to detect and prevent diseases of all forms. What followed on from this visit was a complete transformation in my approach to my own health and wellnessfrom the way I eat to my exercise routine, the supplements I take, and how I interact with my own GP doctor back at home.

Bill F. was looking to live a long life, but more importantly a long, healthy life. Instead of just seeking health insurance, he sought health assurance and declared that he wanted to be active and productive until 100. After the experience, Bill noted, Thankfully they found no problems with [my] brain, cholesterol, or balance, although I learned I needed to lose weight and build muscle mass, and I saw I was susceptible to deep vein thrombosis.

Joe N., a Health Nucleus client, recalled how the Health Nucleus discovered a 2.8cm tumor on his left kidney, only four months after he went through his annual physical. He reports, Because the cancer was caught early, I was fortunately able to have the tumor quickly removed through an outpatient ablation procedure, thus avoiding inevitable chemo and radiation treatments. I now have new baseline metrics for my whole genome, brain health, internal organs, and cardiovascular system that empower me to be even more proactive in managing my health.

The goal of Atelier Health is to deliver the highest-quality medical care by focusing on technology designed to optimize the health span. With the understanding that the root causes of many diseases are based on both genetic and lifestyle factors, the Atelier Health/Health Nucleus partnership is a unique one. The practice also offers traditional concierge medical care. The initial evaluation process generally involves an extensive history and physical followed by a thorough battery of tests. This process may take one or two days, depending on the extent of testing.

[For more on Atelier Healths approach click here]

The integration of genetic analysis, advanced imaging, and biomarkers in a multispecialty platform allows for comprehensive care in both health and disease states. This 360-degree view of the patient creates meaningful discussion centered around cutting-edge therapeutics, nutrition, and fitness.

View post:
Dr. Ram Dandillaya: Take Control of Your Health Today with a Precise and Personalized Assessment - csq.com

After a super-fast DNA test developed by scientists at Imperial College, Helen Rumbelow trialled their new gadget it lets people choose food to suit their genes

The Times,November 12 2019, 12:01am

Will it be my grandmothers cancer, or the family weakness for Alzheimers that will get me in the end? Our genes contain instructions for our death as well as our life, but they have always played dumb. Until now.

Now I can wear a wristband with my genetic vulnerability for fatal diseases coded into it. Which is by turns futuristic and kind of terrifying. For me, its like shaking hands with my heart attack scheduled for 2050: Nice to get to know you at last!

Weird, but I soon get used to it when I take the wristband shopping. Its the opposite experience to taking a toddler, endlessly pestering for sweeties, to the supermarket. When I aim the tiny scanner of the DNA Nudge wristband

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

The rest is here:
DNA Nudge app review: can this wristband tell you the best diet for your genes? - The Times